Phase III MIRANTIBUS trial: results of 48 weeks treatment with divozilimab versus teriflunomide in relapsing multiple sclerosis.

Authors
Category Primary study
ConferenceMultiple Sclerosis Journal
Year 2023
This article has no abstract
Epistemonikos ID: d8585bb035cb23435efe3b03a16d27236e30646f
First added on: Apr 30, 2026